Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | SLC16A1 | P53985 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832938 | 0.91 | SLC16A1 (0.60) | AGTR1AGTR2CYP2C9SLC16A1CYP3A4 | |
| SCHEMBL3828205 | 0.91 | CYP2C9 (0.49) | AGTR1AGTR2CYP2C9SLC16A1CYP3A4 | |
| SCHEMBL3832814 | 0.88 | CYP2C9 (0.51) | AGTR1AGTR2CYP2C9SLC16A1CYP3A4 | |
| SCHEMBL3830041 | 0.84 | SLC16A1 (0.68) | AGTR1AGTR2CYP2C9SLC16A1CYP3A4 | |
| SCHEMBL3833844 | 0.84 | SLC16A1 (0.62) | CYP2C9SLC16A1CYP3A4 | |
| SCHEMBL3826878 | 0.83 | CYP2C9 (0.52) | CYP2C9SLC16A1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL3834003 | 0.82 | SLC16A1 (0.62) | CYP2C9SLC16A1CYP3A4 | |
| SCHEMBL4797431 | 0.80 | SLC16A1 (0.61) | AGTR1AGTR2CYP2C9SLC16A1CYP3A4 | |
| SCHEMBL3847698 | 0.80 | SLC16A1 (0.51) | AGTR1AGTR2CYP2C9SLC16A1CYP3A4 | |
| SCHEMBL3833785 | 0.79 | L3MBTL1 (0.45) | CYP2C9SLC16A1CYP3A4LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | AGTR1 751/4885AGTR2 1470/4885CYP2C9 89/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | AGTR1 670/4885AGTR2 1238/4885CYP2C9 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.